2022
Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors
Numan Y, Rahman Z, Grenet J, Boisclair S, Bewersdorf JP, Collins C, Barth D, Fraga M, Bixby DL, Zeidan AM, Yilmaz M, Desai P, Mannis G, Deutsch YE, Abaza Y, Dinner S, Frankfurt O, Litzow M, Al‐Kali A, Foran JM, Sproat LZ, Jovanovic B, Daver N, Perl AE, Altman JK. Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors. American Journal Of Hematology 2022, 97: 322-328. PMID: 34981560, DOI: 10.1002/ajh.26447.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMyeloid leukemiaRelapsed/Refractory Acute Myeloid LeukemiaComposite complete remission rateRefractory acute myeloid leukemiaLower median overall survivalComplete remission rateMedian overall survivalStem cell transplantCRC ratesLower CRCRefractory FLT3Median survivalRemission rateIntensive inductionOverall survivalCell transplantCombination therapyFLT3 inhibitorsFLT3 mutationsClinical activityUS CentersRetrospective analysisADMIRAL studyMitogen-activated protein kinase pathway
2020
Leukapheresis for the management of hyperleukocytosis in acute myeloid leukemia—A systematic review and meta‐analysis
Bewersdorf JP, Giri S, Tallman MS, Zeidan AM, Stahl M. Leukapheresis for the management of hyperleukocytosis in acute myeloid leukemia—A systematic review and meta‐analysis. Transfusion 2020, 60: 2360-2369. PMID: 32776542, PMCID: PMC8631180, DOI: 10.1111/trf.15994.Peer-Reviewed Original ResearchMeSH KeywordsDisease-Free SurvivalHumansHydroxyureaLeukapheresisLeukemia, Myeloid, AcuteLeukocytosisRandomized Controlled Trials as TopicSurvival RateConceptsAcute myeloid leukemiaEarly mortality rateWhite blood cellsRisk ratioMyeloid leukemiaMortality rateSystematic reviewShort-term mortality benefitHigh early mortality rateManagement of hyperleukocytosisCochrane Central RegisterIndividual study estimatesWeb of ScienceCentral RegisterMortality benefitControlled TrialsPrimary outcomeEarly mortalityRetrospective studyMultiarm studiesTreatment strategiesTwo-armEarly deathLeukapheresisPatients